About hcw biologics inc - HCWB
HCW Biologics Inc. is a biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen health span by disrupting the link between chronic, low-grade inflammation, and age-related diseases. The firm considers age-related low-grade chronic inflammation as a contributing factor to several chronic diseases and conditions, such as cancer, cardiovascular disease, diabetes, neurodegenerative diseases, and autoimmune diseases. The company was founded by Hing C. Wong on April 2, 2018 and is headquartered in Miramar, FL.
HCWB At a Glance
HCW Biologics Inc.
2929 North Commerce Parkway
Miramar, Florida 33025
| Phone | 1-954-842-2024 | Revenue | 54.23K | |
| Industry | Biotechnology | Net Income | -22,298,702.00 | |
| Sector | Health Technology | Employees | N/A | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
HCWB Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | 37.543 |
| Price to Book Ratio | 1.151 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | N/A |
| Enterprise Value to Sales | 127.098 |
| Total Debt to Enterprise Value | 0.988 |
HCWB Efficiency
| Revenue/Employee | 1,549.486 |
| Income Per Employee | -637,105.771 |
| Receivables Turnover | 1.686 |
| Total Asset Turnover | 0.002 |
HCWB Liquidity
| Current Ratio | 0.108 |
| Quick Ratio | N/A |
| Cash Ratio | 0.093 |
HCWB Profitability
| Gross Margin | 19.999 |
| Operating Margin | -24,216.92 |
| Pretax Margin | -14,677.144 |
| Net Margin | -41,117.241 |
| Return on Assets | -81.447 |
| Return on Equity | N/A |
| Return on Total Capital | -232.909 |
| Return on Invested Capital | -1,322.399 |
HCWB Capital Structure
| Total Debt to Total Equity | 246.285 |
| Total Debt to Total Capital | 71.122 |
| Total Debt to Total Assets | 27.77 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |